Cantor Fitzgerald Starts Cara Therapeutics (CARA) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- S&P 500 ends marginally lower as investors focus on US-Iran war
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- US and Iran discuss phased deal to reopen Hormuz and end US blockade, sources say
Janney Capital Resumes Cara Therapeutics (CARA) at Buy
November 4, 2015 7:54 AM ESTJanney Capital resumes coverage on Cara Therapeutics (NASDAQ: CARA) with a Buy rating and a price target of $28.00.
Analyst Ken Trbovich commented, "We believe enrollment in CARA's first proof-of-concept study of oral CR845 is now complete. This places CARA on track to... More
